Group 1 - Monteverde & Associates PC is investigating Coeptis Therapeutics Holdings, Inc. regarding its proposed merger with Z Squared Inc., where Z Squared shareholders will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm operates from the Empire State Building in New York City and emphasizes its national class action securities litigation capabilities [2][3] Group 2 - The firm encourages shareholders with concerns about Coeptis Therapeutics to seek additional information free of charge [3] - Monteverde & Associates PC highlights its litigation experience, including cases that have reached the U.S. Supreme Court [2]

Core Viewpoint - Coeptis Therapeutics Holdings, Inc. and Z Squared Inc. have entered into a definitive merger agreement, resulting in Z Squared becoming a wholly-owned subsidiary of Coeptis, with a focus on Dogecoin mining and a planned spin-out of Coeptis' biopharmaceutical operations [1][5][10] Company Overview - Coeptis Therapeutics is a biopharmaceutical and technology company that develops innovative cell therapy platforms for cancer, autoimmune, and infectious diseases [1][6] - Z Squared Inc. specializes in digital asset mining, primarily focusing on Dogecoin, which has a market capitalization exceeding $20 billion [2][10] Merger Details - The merger will involve a wholly-owned subsidiary of Coeptis merging with Z Squared, with Z Squared shareholders receiving equity in Coeptis in exchange for 9,000 U.S.-based Dogecoin mining machines [1] - The transaction is expected to close in the third quarter of 2025, pending regulatory approvals and shareholder consent [1] Leadership Changes - Post-merger, Z Squared executives will lead the combined entity, with David Halabu as CEO and Michelle Burke as COO [3][4] - Current Coeptis CEO Dave Mehalick will exit the Board of Directors upon closing [3] Strategic Focus - The combined company aims to create the largest publicly-traded entity in the U.S. focused on Dogecoin mining, targeting both retail and institutional investors [5] - Coeptis plans to maintain its biopharmaceutical operations separately after the merger, allowing continued involvement in both sectors [5]

Strategic Collaboration Enhances Access to Cutting-Edge AI, Blockchain Solutions, Biopharma & Defense TechnologiesWEXFORD, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is excited to announce the establishment of a new co-working technology hub in India in partnership with U.S.-based NexGenAI Solutions Group (https://nexgenai.io) and Indian technology firm Ishvara Tech Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39669 Coeptis Therapeutics Holdings, Inc. (Exact name of registrant as specified in it ...

Core Insights - COEPTIS, Inc. has formed a majority-owned subsidiary, GEAR Therapeutics, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for various cancers and therapeutic modalities [1] - The GEAR™ Cell Therapy Platform offers a first-in-class approach to modifying immune cells, aiming to enhance remission rates in patients with hematologic malignancies and other cancers [1] - GEAR-NK cells are designed to be co-administered with targeted monoclonal antibodies, potentially improving treatment outcomes by avoiding neutralization by mAb therapy [2][3] Company Developments - COEPTIS has successfully licensed exclusive worldwide development and commercialization rights to the GEAR platform from VyGen-Bio, Inc., expanding its ownership and capabilities in the biotechnology sector [1][4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a commitment to improving patient outcomes through advanced research [5][6] - COEPTIS has established a Technology Division to enhance operational capabilities, incorporating AI-powered marketing software and robotic process automation tools [7] Market Potential - The GEAR technology is expected to address significant therapeutic needs in the market, providing a cost-effective option for patients requiring advanced cancer therapies [4] - The GEAR platform also has the potential to modify hematopoietic stem cells in combination with mAbs, which could improve bone marrow transplant outcomes for hematological malignancies [2]

The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain TechnologyWEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-s ...

Core Viewpoint - COEPTIS, Inc. has announced a strategic partnership with MarketLeverage to enhance affiliate marketing through AI technology integration, aiming to improve marketing efficiency and performance-based strategies [1][2][3]. Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative biotechnology solutions, including cell therapy platforms for various diseases [7][8]. - The company has established a Technology Division that includes AI-powered marketing software and robotic process automation tools to optimize business processes [9]. Partnership Details - The collaboration between COEPTIS' NexGenAI Affiliates Network and MarketLeverage will leverage advanced automation and data-driven insights to empower affiliates, brands, and marketers [2][4]. - MarketLeverage has a vast network, currently working with 5,500 advertisers and 55,000 publishers, which will enhance the reach and effectiveness of the partnership [2][10]. Market Insights - The artificial intelligence in marketing market is projected to grow from $27.83 billion in 2024 to $35.54 billion in 2025, with a compound annual growth rate (CAGR) of 27.7% [5]. - The market is expected to reach $106.54 billion by 2029, with a CAGR of 31.6%, indicating significant growth potential in the AI-driven marketing sector [5]. Technological Advancements - NexGenAI Affiliates Network provides AI-driven tools for campaign management, predictive analytics, and automated outreach, enhancing the capabilities of affiliates and advertisers [4][11]. - The partnership aims to create a new frontier in performance marketing by combining MarketLeverage's extensive network with NexGenAI's automated tools [3][4].

Core Insights - COEPTIS, Inc. has announced a partnership with MarketLeverage to integrate AI technology into affiliate marketing, aiming to enhance performance-based strategies [1][2][3] - The collaboration will leverage MarketLeverage's extensive network of 5,500 advertisers and 55,000 publishers to drive traffic and improve marketing efficiency [2][3] - The partnership is expected to transform digital marketing by providing affiliates and brands with advanced automation and data-driven insights [3][4] Company Overview - COEPTIS, Inc. is a biopharmaceutical and technology company focused on innovative cell therapy platforms and advanced technologies [7][9] - The company has established a Technology Division that includes AI-powered marketing software and robotic process automation tools [9] - COEPTIS aims to improve patient outcomes through cutting-edge research and development efforts in the biopharmaceutical sector [7][8] Market Trends - The artificial intelligence in marketing market is projected to grow from $27.83 billion in 2024 to $35.54 billion in 2025, reflecting a compound annual growth rate (CAGR) of 27.7% [5] - By 2029, the market size is expected to reach $106.54 billion, with a CAGR of 31.6%, indicating significant growth potential in the AI-driven marketing sector [5]

Core Perspective - COEPTIS, Inc. has launched COEP Venture Group, an investment arm focused on funding and accelerating technology startups in AI, Robotic Process Automation (RPA), and AI Agents [1][2][3] Investment Strategy - COEP Venture Group aims to identify and support high-potential startups that are shaping the future of automation and intelligent systems by providing capital, mentorship, and access to industry networks [2][3] - The investment focus includes advanced machine learning models, AI-driven enterprise solutions, RPA, AI agents, and other emerging technologies such as blockchain and data analytics [8] Leadership and Expertise - Michael Woloshin, a seasoned entrepreneur with extensive experience in technology and marketing automation, will lead COEP Venture Group, leveraging his background to foster innovation and expand market opportunities for emerging tech companies [5] Strategic Initiatives - COEP Venture Group will utilize NexGenAI Solutions Group to provide marketing services to its portfolio companies, ensuring they receive not only funding but also strategic exposure and market positioning [4]

Core Insights - COEPTIS, Inc. successfully closed an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million, indicating strong investor confidence in the company's innovative therapeutic solutions and technology-driven growth [1][2][3] Financing Details - The financing round was led by CJC Investment Trust, controlled by board member Christopher Calise, who increased their initial investment [2] - The Series A Preferred shares are convertible into common stock at a price of $8.00 per share, with investors receiving a 15% equity interest in newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. [2] Use of Proceeds - The funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes, alongside enhancing operational capabilities through AI-driven tools from the NexGenAI Affiliates Network platform [3][4] - The additional capital will accelerate the integration of advanced AI solutions and automation capabilities, improving research processes and overall operational efficiency [3] Company Strategy - COEPTIS aims to drive innovation in technology and AI while fostering a culture of responsible innovation to create a self-sustaining business model for long-term success and profitability [4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a therapeutic portfolio that includes assets licensed from Deverra Therapeutics [5][6] Technology Division - A newly established Technology Division will enhance operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [6]